| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Spiro Pavlopoulos, Ganesh A Thakur, Spyros P Nikas, Alexandros Makriyanni. Cannabinoid receptors as therapeutic targets. Current pharmaceutical design. vol 12. issue 14. 2006-08-01. PMID:16712486. |
the cannabinoid receptors cb1 and cb2 are family a, g-protein coupled receptors that mediate the effects of cannabinoids, a class of compounds that are so named because the first members were isolates of the cannabis plant. |
2006-08-01 |
2023-08-12 |
Not clear |
| Erica J Carrier, John A Auchampach, Cecilia J Hillar. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proceedings of the National Academy of Sciences of the United States of America. vol 103. issue 20. 2006-07-28. PMID:16672367. |
the plant-derived cannabinoids delta9-tetrahydrocannabinol (thc) and cannabidiol (cbd) both have immunosuppressive effects; although some effects of thc are mediated by the cb2 receptor, cb2 binds cbd weakly. |
2006-07-28 |
2023-08-12 |
mouse |
| F Massa, K Monor. Endocannabinoids and the gastrointestinal tract. Journal of endocrinological investigation. vol 29. issue 3 Suppl. 2006-06-29. PMID:16751708. |
delta9-tetrahydrocannabinol (thc; the active component of marijuana), as well as endogenous and synthetic cannabinoids, exert their biological functions on the gastrointestinal tract by activating two types of cannabinoid receptors, cannabinoid type 1 receptor (cb1 receptor) and cannabinoid type 2 receptor (cb2 receptor). |
2006-06-29 |
2023-08-12 |
Not clear |
| Kitty C M Verhoeckx, Henrie A A J Korthout, A P van Meeteren-Kreikamp, Karl A Ehlert, Mei Wang, Jan van der Greef, Richard J T Rodenburg, Renger F Witkam. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. International immunopharmacology. vol 6. issue 4. 2006-04-26. PMID:16504929. |
unheated cannabis sativa extracts and its major compound thc-acid have potential immuno-modulating properties not mediated by cb1 and cb2 receptor coupled pathways. |
2006-04-26 |
2023-08-12 |
Not clear |
| Stéphane Vignot, Benjamin Besse, Thibault de la Motte Rouge, Christophe Massard, Jean-Philippe Spano, Laurent Karil. [Cannabis and cancer]. Bulletin du cancer. vol 93. issue 2. 2006-04-25. PMID:16517414. |
the most abundant molecule, delta9-tetrahydrocannabinol (thc), is involved in the biological effects of cannabis due to its analogy with endogenous substances (endocannabinoids) thus activating specific receptors : cb1 and cb2. |
2006-04-25 |
2023-08-12 |
Not clear |
| Uberto Pagotto, Giovanni Marsicano, Daniela Cota, Beat Lutz, Renato Pasqual. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine reviews. vol 27. issue 1. 2006-03-16. PMID:16306385. |
cannabinoid receptors, named cb1 receptor and cb2 receptor, first discovered as the molecular targets of the psychotropic component of the plant cannabis sativa, participate in the physiological modulation of many central and peripheral functions. |
2006-03-16 |
2023-08-12 |
Not clear |
| Mario van der Stelt, Vincenzo Di Marz. Cannabinoid receptors and their role in neuroprotection. Neuromolecular medicine. vol 7. issue 1-2. 2005-12-08. PMID:16052037. |
two g protein-coupled receptors for marijuana's psychoactive component, delta9-tetrahydrocannabinol, have been cloned to date, the cannabinoid cb1 and cb2 receptors. |
2005-12-08 |
2023-08-12 |
Not clear |
| Robert F Schwabe, Soeren V Siegmun. Potential role of CB2 receptors in Cannabis smokers with chronic hepatitis C. Hepatology (Baltimore, Md.). vol 42. issue 4. 2005-11-07. PMID:16175591. |
potential role of cb2 receptors in cannabis smokers with chronic hepatitis c. |
2005-11-07 |
2023-08-12 |
Not clear |
| Christophe Hézode, Françoise Roudot-Thoraval, Son Nguyen, Pascale Grenard, Boris Julien, Elie-Serge Zafrani, Jean-Michel Pawlotsky, Jean-Michel Pawlostky, Daniel Dhumeaux, Sophie Lotersztajn, Ariane Malla. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology (Baltimore, Md.). vol 42. issue 1. 2005-08-02. PMID:15892090. |
daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis c. cannabinoids present in cannabis sativa (marijuana) exert biological effects via cannabinoid receptors cb1 and cb2. |
2005-08-02 |
2023-08-12 |
Not clear |
| Ester Fride, Cfir Feigin, Datta E Ponde, Aviva Breuer, Lumír Hanus, Nina Arshavsky, Raphael Mechoula. (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. European journal of pharmacology. vol 506. issue 2. 2005-05-06. PMID:15588739. |
delta9-tetrahydrocannabinol (delta9-thc) and (-)-cannabidiol are major constituents of the cannabis sativa plant with different pharmacological profiles: (-)-delta9-tetrahydrocannabinol, but not (-)-cannabidiol, activates cannabinoid cb1 and cb2 receptors and induces psychoactive and peripheral effects. |
2005-05-06 |
2023-08-12 |
mouse |
| Boris Julien, Pascale Grenard, Fatima Teixeira-Clerc, Jeanne Tran Van Nhieu, Liying Li, Meliha Karsak, Andreas Zimmer, Ariane Mallat, Sophie Lotersztaj. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology. vol 128. issue 3. 2005-04-06. PMID:15765409. |
cannabinoids are the active components of marijuana and act via 2 g-protein-coupled receptors, cb1 and cb2. |
2005-04-06 |
2023-08-12 |
Not clear |
| P Sacerdote, C Martucci, A Vaccani, F Bariselli, A E Panerai, A Colombo, D Parolaro, P Mass. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. Journal of neuroimmunology. vol 159. issue 1-2. 2005-03-18. PMID:15652407. |
cannabidiol dose-dependently decreased fmlp-induced chemotaxis of macrophages, and the cb2 receptor antagonist prevented this decrease. |
2005-03-18 |
2023-08-12 |
Not clear |
| Matthew J McFarland, Eric L Barke. Anandamide transport. Pharmacology & therapeutics. vol 104. issue 2. 2005-02-17. PMID:15518883. |
n-arachidonylethanolamine (anandamide) is an endogenous agonist of the cannabinoid cb1 and cb2 receptors and displays many of the same receptor-mediated physiological effects as delta9-tetrahydrocannabinol (delta9-thc), the active component of marijuana. |
2005-02-17 |
2023-08-12 |
Not clear |
| Allyn C Howlett, Christopher S Breivogel, Steven R Childers, Samuel A Deadwyler, Robert E Hampson, Linda J Porrin. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology. vol 47 Suppl 1. 2004-12-20. PMID:15464149. |
delta9-tetrahydrocannabinol from cannabis sativa is mimicked by cannabimimetic analogs such as cp55940 and win55212-2, and antagonized by rimonabant and sr144528, through g-protein-coupled receptors, cb1 in the brain, and cb2 in the immune system. |
2004-12-20 |
2023-08-12 |
Not clear |
| Laurent Venance, Raphael Maldonado, Olivier Manzon. [Endocannabinoids in the central nervous system]. Medecine sciences : M/S. vol 20. issue 1. 2004-09-09. PMID:14770363. |
the major psychoactive component of cannabis derivatives, delta9-thc, activates two g-protein coupled receptors: cb1 and cb2. |
2004-09-09 |
2023-08-12 |
Not clear |
| Franjo Grotenherme. Pharmacology of cannabinoids. Neuro endocrinology letters. vol 25. issue 1-2. 2004-08-03. PMID:15159677. |
dronabinol (delta 9-tetrahydocannabinol, thc), the main source of the pharmacological effects caused by the use of cannabis, is an agonist to both the cb1 and the cb2 subtype of cannabinoid receptors. |
2004-08-03 |
2023-08-12 |
Not clear |
| B Park, H M Gibbons, M D Mitchell, M Glas. Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. Placenta. vol 24. issue 10. 2004-07-15. PMID:14580383. |
synthetic cannabinoids, the psychoactive components of the cannabis sativa (marijuana) plant and their endogenous counterparts, act through two g protein-coupled receptors, cb1 and cb2. |
2004-07-15 |
2023-08-12 |
human |
| Malcolm Begg, Fong-Ming Mo, László Offertaler, Sándor Bátkai, Pál Pacher, Raj K Razdan, David M Lovinger, George Kuno. G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current. The Journal of biological chemistry. vol 278. issue 46. 2003-12-24. PMID:12952947. |
the cannabinoid analog "abnormal cannabidiol" (abn-cbd) causes endothelium-dependent vasodilation in rat isolated mesenteric arteries through a g protein-coupled receptor distinct from cb1 or cb2. |
2003-12-24 |
2023-08-12 |
human |
| Malcolm Begg, Fong-Ming Mo, László Offertaler, Sándor Bátkai, Pál Pacher, Raj K Razdan, David M Lovinger, George Kuno. G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current. The Journal of biological chemistry. vol 278. issue 46. 2003-12-24. PMID:12952947. |
this potentiation was abolished by the cannabidiol analog o-1918 or by pertussis toxin but was unaffected by cb1 or cb2 antagonists. |
2003-12-24 |
2023-08-12 |
human |
| B Park, H M Gibbons, M D Mitchell, M Glass. Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. Placenta. vol 24. issue 5. 2003-12-10. PMID:12744923. |
synthetic cannabinoids, the psychoactive components of the cannabis sativa (marijuana) and their endogenous counterparts, act through two g protein-coupled receptors, cb1 and cb2. |
2003-12-10 |
2023-08-12 |
human |